• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PIQ

PROTEOMICS INTERNATIONAL LABORATORIES LTD

0.00% ! 34.0¢
Market Cap $55.65M  !
Healthcare Biotechnology
Add to My Watchlist

Proteomics International Laboratories Ltd is an Australia-based medical technology... Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PIQ
Ann: Collaboration expanded to advance Endometriosis blood test
2
14/11/25 77 10K
14/11/25 Last post  bar Comments Created with Sketch.  77  Views Created with Sketch.  10K 
PIQ
Ann: Proteomics International receives $2.2m in R&D tax incentive 		12/11/25 0 185
12/11/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  185 
PIQ
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
2
07/11/25 81 10K
07/11/25 Last post  Bullrush007 Comments Created with Sketch.  81  Views Created with Sketch.  10K 
PIQ
Ann: PromarkerEndo test for endometriosis receives $0.5m grant 		06/11/25 3 658
06/11/25 Last post  MorteinFastest Comments Created with Sketch.  3  Views Created with Sketch.  658 
PIQ
Ann: Next-Gen PromarkerD test performance results published
2 3
24/10/25 155 29K
24/10/25 Last post  dsa69 Comments Created with Sketch.  155  Views Created with Sketch.  29K 
PIQ
Ann: Notice of Annual General Meeting/Proxy Form 		22/10/25 0 172
22/10/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  172 
PIQ
Ann: Initial Directors Interest Notice 		11:52 2 363
11:52 Last post  Bullrush007 Comments Created with Sketch.  2  Views Created with Sketch.  363 
PIQ
Ann: Appointment of Director 		02:11 8 1.0K
02:11 Last post  Gillysrooms Comments Created with Sketch.  8  Views Created with Sketch.  1.0K 

See All Discussions arrow Created with Sketch.

Timeline

Proteomics International receives $2.2m in R&D tax incentive
12 Nov 09:04
 
PromarkerEndo test for endometriosis receives $0.5m grant
06 Nov 13:51
 
Quarterly Activities/Appendix 4C Cash Flow Report
27 Oct 09:50
 
Notice of Annual General Meeting/Proxy Form
22 Oct 14:21
 
Initial Directors Interest Notice
15 Oct 11:00
 
Collaboration expanded to advance Endometriosis blood test
15 Oct 08:33
 
View More arrow Created with Sketch.

Featured News

NEWS Webjet nosedives on lower domestic travel demand; blames just about everything
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast – Is lithium back?
right-arrow Created with Sketch.
LM1 New Gold Hits Extend Marda Trend for Leeuwin
right-arrow Created with Sketch.
NEWS Renerve pops +80% as US defence, veterans affairs depts approve nerve healing product
right-arrow Created with Sketch.
NEWS View the latest ASX news here
right-arrow Created with Sketch.
NEWS Investor fury as DroneShield sinks -33% after CEO sells all shares at ~$3.30
right-arrow Created with Sketch.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
34.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $55.65M
Open High Low Value Volume
34.0¢ 34.0¢ 33.5¢ $36.80K 109.7K

Buyers (Bids)

No. Vol. Price($)
3 95471 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 17598 3
View Market Depth
Last trade - 16.10pm 14/11/2025 (20 minute delay) ?
PIQ (ASX) Chart

Top Stories

HotCopper Highlights: Droneshield, what the hell? Plus MinRes' $1B steal; Life360 & more

Good Afternoon and welcome to HotCopper Highlights for Week 46, I’m Jon Davidson. In this segment the stocks you were watching and discussing the most this week, for better or worse @ let’s get into it starting with the most viewed.Listen to the HotCopper podcast f...
Week 46 Wrap: I feel like the Santa Rally isn't going to happen this year either. Also, Simandou is here Well, what a week it’s been. The ASX200 is back down to the 8,640s as I write this (at 2.25pm AEDT) and that means 1Y returns for the index are down to +5%. Not that long ago, the XJO was looking at YTD returns of +10% when the US-Australia critical minerals deal was the flavour o...
Listen: HotCopper Wire Podcast 031 – Is lithium back? In this HotCopper Wire W46 episode, we talk about lithium's supposed revival (especially with how the spodumene prices have been tracking).
Leeuwin Metals hits grades over 7g/t in latest drilling at WA Goldfields' Evanston target Leeuwin Metals has unveiled multiple drill hits intersecting gold on-site at Marda at the Evanston target in WA's prolific goldfields region.
PYC reports Phase II success in treating degenerative blindness condition PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 18 months after treatment. Listen to the HotCopper podcast...

Featured News

NEWS Renerve pops +80% as US defence, veterans affairs depts approve nerve healing product
right-arrow Created with Sketch.
LM1 New Gold Hits Extend Marda Trend for Leeuwin
right-arrow Created with Sketch.
NEWS Investor fury as DroneShield sinks -33% after CEO sells all shares at ~$3.30
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast – Is lithium back?
right-arrow Created with Sketch.
NEWS Commonwealth dumps in W46 after market really didn't like Comyn's 'copycat competitors' claims
right-arrow Created with Sketch.
NEWS View the latest ASX news here
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.